A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma.

Source:http://linkedlifedata.com/resource/pubmed/id/17410188

Download in:

View as

Triples

General Info

PMID
17410188